Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Feb;47(2):125-34.
doi: 10.1002/ppul.21525. Epub 2011 Aug 9.

Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis

Collaborators, Affiliations
Randomized Controlled Trial

Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis

Nicole Mayer-Hamblett et al. Pediatr Pulmonol. 2012 Feb.

Abstract

Rationale: The risk of pulmonary exacerbation following Pseudomonas aeruginosa (Pa) acquisition in children with cystic fibrosis (CF) is unknown.

Objectives: To determine if failure of antibiotic therapy to eradicate Pa and frequency of Pa recurrence are associated with increased exacerbation risk.

Methods: The cohort included 282 children with CF who participated in the EPIC trial ages 1-12 with newly acquired Pa, defined as either a first lifetime Pa positive respiratory culture or positive after two years of negative cultures (past isolation of Pa but >2 years prior to the trial). All received antibiotics to promote initial eradication followed by 15 months of intermittent maintenance antibiotics. Quarterly cultures were used to define initial eradication success and subsequent number of Pa recurrences. A standardized symptom-based definition of exacerbation was utilized. Cox proportional hazards models were used to estimate exacerbation risk.

Results: Failure to initially eradicate Pa was associated with exacerbation risk (hazard ratio [HR]: 2.49, 95% confidence interval [CI] 1.26, 4.93). In 245/282 with successful initial eradication during the trial, past isolation of Pa >2 years before the trial was the most significant predictor of exacerbation (HR 1.62, 95% CI 1.12, 2.35). In 37/282 who failed initial eradication, persistent Pa during the maintenance phase (1 or more Pa recurrences after failure to initially eradicate) added even greater exacerbation risk (HR 4.13, 95% CI 1.28, 13.32).

Conclusions: Children with CF who fail to eradicate after initial antibiotic treatment are at higher risk of subsequent exacerbation, suggesting clinical benefit to successful early eradication of Pa infection.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan Meier plot of time to first pulmonary exacerbation treated with either IV antibiotics (a and c) or antibiotics by any route of administration (b and d), comparing those with newly acquired Pa who entered the trial with no history of Pa colonization versus those who entered with past isolation of Pa (>2 years prior to enrollment) (a and b), and those who achieved successful initial eradication at week 10 to those who failed to achieve successful initial eradication (c and d).
Figure 2
Figure 2
Distribution of the number of Pa positive cultures from week 10 through the end of the 15-month maintenance phase for subgroups defined by initial eradication success at week 10.

References

    1. Ratjen F, Döring G. Cystic fibrosis. Lancet. 2003;361:681–689. - PubMed
    1. Gibson RL, Burns JL, Ramsey BW. State of the art: pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168:918–951. - PubMed
    1. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol. 1992;12:158–161. - PubMed
    1. Courtney JM, Bradley J, Mccaughan J, et al. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol. 2007;42:525–532. - PubMed
    1. Nixon GM, Armstrong DS, Carzino R, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr. 2001;138:699–704. - PubMed

Publication types